| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
9 analysts have expressed a variety of opinions on Penumbra (NYSE:PEN) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 5 | 1 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 1 | 0 | 0 | 0 |
| 3M Ago | 3 | 3 | 1 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Penumbra, presenting an average target of $305.11, a high estimate of $350.00, and a low estimate of $266.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 0.7%.
The standing of Penumbra among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Vijay Kumar | Evercore ISI Group | Lowers | Outperform | $285.00 | $300.00 |
| Vijay Kumar | Evercore ISI Group | Announces | Outperform | $300.00 | - |
| Kallum Titchmarsh | Morgan Stanley | Raises | Equal-Weight | $266.00 | $260.00 |
| David Rescott | Truist Securities | Raises | Buy | $310.00 | $300.00 |
| Priya Sachdeva | UBS | Raises | Buy | $335.00 | $330.00 |
| Shagun Singh | RBC Capital | Lowers | Outperform | $325.00 | $330.00 |
| David Rescott | Baird | Raises | Outperform | $285.00 | $283.00 |
| Larry Biegelsen | Wells Fargo | Lowers | Overweight | $290.00 | $315.00 |
| Jason Mills | Canaccord Genuity | Raises | Buy | $350.00 | $340.00 |
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Penumbra's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Penumbra analyst ratings.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Penumbra's revenue growth over a period of 3M has been noteworthy. As of 30 June, 2025, the company achieved a revenue growth rate of approximately 13.38%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Penumbra's net margin excels beyond industry benchmarks, reaching 13.34%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Penumbra's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.61% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.77%, the company showcases effective utilization of assets.
Debt Management: Penumbra's debt-to-equity ratio is below the industry average. With a ratio of 0.17, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: PEN
